Let's keep hoping...
A Seattle-based biotech firm, has received a $2.4 million grant to develop CTT2274, a new drug for metastatic prostate cancer. CTT2274 is a small molecule drug conjugate that targets PSMA. This targeted approach delivers a toxic payload, MMAE, directly to tumor cells, potentially minimizing side effects and maximizing effectiveness. Preclinical studies in mice have shown CTT2274 can lead to tumor remission and increased survival. CTT plans to conduct further studies and file an Investigational New Drug application, aiming for clinical trials in 2026.
I checked some of their graphs, to be clear: in mice models you cannot see a single decrease in survival for the whole observation time (100% alive at 91 days while the control group was 100% died at 56 days), I wish we were more like mice!
The Existence of the Oligometastatic State in Prostate Cancer (and other cancers)
“Ancient Virus” Therapy for Prostate Cancer Receives DOD Grant, Genetic Engineering & Biotechnology News (GEN), April 27, 2023
BCR May Not Be a Strong Surrogate End Point for Prostate Cancer Survival